Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of A/H7N9 and A/H3N2v Influenza Vaccines in Healthy Adults
NCT02921997Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2016
- Primary completion
- Mar 2017
- Modality
- Transdermal Patches, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of monovalent influenza A/H7N9 virus vaccine, influenza A/H3N2v vaccine in Avian Influenza (AI), influenza, sponsored by National Institute of Allergy and Infectious Diseases. Started Nov 2016; status: completed.
02
Drugs
monovalent influenza A/H7N9 virus vaccineinfluenza A/H3N2v vaccine
03
Conditions
Avian Influenza (AI)influenza
Beyond the preview
Go deeper on NCT02921997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921997.